Engineered anti-EGFRvIII targeted exosomes induce apoptosis in glioblastoma multiforme

References

• Ren J, He W, Zheng L, et al. From structures to functions: insights into exosomes as promising drug delivery vehicles. Biomater Sci. 2016;4(6):910–921.
   PubMed Web of Science ®Google Scholar
• Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–383.
   PubMed Web of Science ®Google Scholar
• Moon B, Chang S. Exosome as a delivery vehicle for cancer therapy. Cells. 2022;11(3):316.
   PubMed Web of Science ®Google Scholar
• Krishnan ST, Rudd D, Rahmani R, et al. Nanostructured silicon enabled HR-MS for the Label-Free detection of biomarkers in colorectal cancer plasma small extracellular vesicles. J Nanothernostics. 2022;3(4):189–202.
   Google Scholar
• Kibria G, Ramos EK, Wan Y, et al. Exosomes as a drug delivery system in cancer therapy: potential and challenges. Mol Pharm. 2018;15(9):3625–3633.
   PubMed Web of Science ®Google Scholar
• Ruan S, Zhou Y, Jiang X, et al. Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release. Adv Sci (Weinh). 2021;8(9):2004025.
   PubMedGoogle Scholar
• Heidarzadeh M, Gürsoy-Özdemir Y, Kaya M, et al. Exosomal delivery of therapeutic modulators through the blood–brain barrier; promise and pitfalls. Cell Biosci. 2021;11(1):1–28.
   PubMed Web of Science ®Google Scholar
• Ramos-Zaldívar HM, Polakovicova I, Salas-Huenuleo E, et al. Extracellular vesicles through the blood–brain barrier: a review. Fluids Barriers CNS. 2022;19(1):1–15.
   PubMed Web of Science ®Google Scholar
• Banks WA, Sharma P, Bullock KM, et al. Transport of extracellular vesicles across the blood-brain barrier: brain pharmacokinetics and effects of inflammation. Int J Mol Sci. 2020;21(12):4407.
   PubMed Web of Science ®Google Scholar
• Wu W, Klockow JL, Zhang M, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780.
   PubMed Web of Science ®Google Scholar
• Yang J, Yan J, Liu B. Targeting EGFRvIII for glioblastoma multiforme. Cancer Lett. 2017;403:224–230.
   PubMed Web of Science ®Google Scholar
• Abbott RC, Verdon DJ, Gracey FM, et al. Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma. Clin Transl Immunol. 2021;10(5):e1283.
   PubMed Web of Science ®Google Scholar
• Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16(6):748–754.
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Suki D, Yang D, et al. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med. 2005;3(1):38–36.
   PubMedGoogle Scholar
• Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate glioblastoma: clinical challenges and advances. Clin Transl Med. 2018;7(1):1–12.
   PubMedGoogle Scholar
• Kwiatkowska A, Nandhu MS, Behera P, et al. Strategies in gene therapy for glioblastoma. Cancers (Basel). 2013;5(4):1271–1305.
   PubMedGoogle Scholar
• Asadi-Moghaddam K, Chiocca EA. Chapter 22 – Prodrug-activation gene therapy. In: Kaplitt MG, During MJ, editors. Gene therapy of the Central nervous system. Amsterdam: Academic Press; 2006. p. 291–301.
   Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Ghaemi S, Fekrirad Z, Zamani N, et al. Non-coding RNAs enhance the apoptosis efficacy of therapeutic agents used for the treatment of glioblastoma multiform. J Drug Target. 2022;30(6):589–602.
   PubMed Web of Science ®Google Scholar
• Chang T-C, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745–752.
   PubMed Web of Science ®Google Scholar
• Li Y, Guessous F, Zhang Y, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69(19):7569–7576.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Johnson LA, Davis JL, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 2012;23(10):1043–1053.
   PubMed Web of Science ®Google Scholar
• Stringer BW, Day BW, D’Souza RCJ, et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. Sci Rep. 2019;9(1):1–14.
   PubMedGoogle Scholar
• Omasits U, Ahrens CH, Müller S, et al. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics. 2014;30(6):884–886.
   PubMed Web of Science ®Google Scholar
• Druzhkova T, Yakovlev A. Exosome drug delivery through the blood–brain barrier: experimental approaches and potential applications. Neurochem J. 2018;12(3):195–204.
   Google Scholar
• Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res. 2015;32(6):2003–2014.
   PubMed Web of Science ®Google Scholar
• Zhang M, Jin K, Gao L, et al. Methods and technologies for exosome isolation and characterization. Small Methods. 2018;2(9):1800021.
   Web of Science ®Google Scholar
• Caponnetto F, Manini I, Skrap M, et al. Size-dependent cellular uptake of exosomes. Nanomedicine. 2017;13(3):1011–1020.
   PubMed Web of Science ®Google Scholar
• Choi H, Yim H, Park C, et al. Targeted delivery of exosomes armed with anti-cancer therapeutics. Membranes. 2022;12(1):85.
   PubMed Web of Science ®Google Scholar
• Reagan MR, Kaplan DL. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells. 2011;29(6):920–927.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhou Y, Li H-J. Advances in mesenchymal stem cell exosomes: a review. Stem Cell Res Ther. 2021;12(1):1–12.
   PubMed Web of Science ®Google Scholar
• Mizrak A, Bolukbasi MF, Ozdener GB, et al. Genetically ­engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther. 2013;21(1):101–108.
   PubMed Web of Science ®Google Scholar
• Erkan EP, Senfter D, Madlener S, et al. Extracellular vesicle-mediated suicide mRNA/protein delivery inhibits glioblastoma tumor growth in vivo. Cancer Gene Ther. 2017;24(1):38–44.
   PubMed Web of Science ®Google Scholar
• Luan S, Sun L, Huang F. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Arch Med Res. 2010;41(2):67–74.
   PubMed Web of Science ®Google Scholar
• Gao H. Perspectives on dual targeting delivery systems for brain tumors. J Neuroimmune Pharmacol. 2017;12(1):6–16.
   PubMed Web of Science ®Google Scholar